Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today’s clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.
Proteomedix enables personalized medicine by developing non-invasive diagnostic tests to detect and assess the prognosis of cancer, as well as to match patients with safer and more effective therapies. The first product is a blood-based test for the early diagnosis of prostate cancer. The main benefit of this test is a significantly higher accuracy compared to today’s clinical standard (blood-based PSA test). This reduces unnecessary biopsies and thus results in significant cost savings for the healthcare system and less discomfort for the patient.
Company Information
- Industry
- Company Type
- Privately Held
- Founded
- 2010
- Employee Range
- 1-10
- Revenue Range
- Not available
Location
- Address
- Wagistrasse 21 Schlieren
- City
- Zurich
- Region
- Zurich
- Postal Code
- 8952
- Country
- Switzerland